Diffuse large B-cell lymphoma, multilocalized and extranodal in adult with complete remission: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250017Keywords:
Diffuse large B-cell lymphoma, Lymphoproliferative, ImmunohistochemistryAbstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of lymphomas. The current classification recognizes an expanding group of distinct entities, with this being the most common. Up to one-third of DLBCL cases may originate in nearly any organ, most commonly in the gastrointestinal tract, skin and soft tissues, bones, or genitourinary tract. A 52-year-old woman with no history of chronic degenerative diseases presented with severe abdominal pain, weight loss, and night sweats. As part of her evaluation, an abdominopelvic CT scan was performed, revealing splenomegaly with internal nodular lesions of undetermined origin, inguinal lymphadenopathy, and cutaneous involvement. A lymphoproliferative process was suggested among the differential diagnoses. Immunohistochemical studies confirmed DLBCL. The patient subsequently received treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), achieving a cure rate of approximately 50% after six cycles with an adequate response to treatment.
Metrics
References
De Leval L, Jaffe ES. Lymphoma classification. Cancer J. 2020;26:176–85. DOI: https://doi.org/10.1097/PPO.0000000000000451
Swerdlow SH, World Health Organization, International Agency for Research on Cancer WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer. 2017.
Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720‐48. DOI: https://doi.org/10.1038/s41375-022-01625-x
Campo E, Jaffe ES, Cook JR. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140(11):1229‐53.
Oliveira JL, Grogg KL, Macon WR. Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases. Am J Surg Pathol. 36:1364-70. DOI: https://doi.org/10.1097/PAS.0b013e31825e63a9
Durani U, Ansell SM (2021) CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk Lymphoma. 2021;62:3078-86. DOI: https://doi.org/10.1080/10428194.2021.1953010
Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89(3):310–4. DOI: https://doi.org/10.1002/ajh.23638
Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, et al. Primary lymphomas of the genitourinary tract: A population-based study. Asian J Urol. 2020;7:332–9. DOI: https://doi.org/10.1016/j.ajur.2019.11.002
Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92(8):806-13. DOI: https://doi.org/10.1002/ajh.24797
El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):45-9. DOI: https://doi.org/10.1002/ajh.24169
Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(1):22–32. DOI: https://doi.org/10.1182/blood-2014-05-577189
Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12–23. DOI: https://doi.org/10.1038/nrclinonc.2013.197
Bachy E, Salles G. Treatment approach to newly diagnosed diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):107–18. DOI: https://doi.org/10.1053/j.seminhematol.2015.01.001
Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2:498–505. DOI: https://doi.org/10.1182/asheducation-2011.1.498
Downloads
Published
How to Cite
Issue
Section
